Literature DB >> 16231171

[Therapy and prevention of hyperthyroidism].

U Woenckhaus1, C Girlich.   

Abstract

A decreased serum TSH level can be observed in more than 10% of the German population. Although treatment is not mandatory in each of these cases patients with an unrecognized autonomous thyroid dysfunction have a substantial risk of developing thyrotoxicosis when exposed to large amounts of iodine. Thionamid drugs in combination with potassium perchlorate are given for preventive and therapeutic reasons until definitive thyroidectomy or radioiodine therapy is performed. In younger patients Graves' disease is the main cause of hyperthyroidism. Medical treatment with antithyroid drugs is established to render patients euthyroid. Having decreased the dose as far as possible, drug therapy is continued for 12-18 months to achieve a maximum rate of permanent remission. Ongoing clinical research aims to characterize clinical or laboratory predictors associated with a high risk of relapse after medication is stopped. Selenium supplementation is proposed to be a new therapeutic approach for autoimmune thyroid disease. It is already used quite liberally although data of powerful randomized trials are not available.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16231171     DOI: 10.1007/s00108-005-1508-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

Review 1.  The effects of amiodarone on the thyroid.

Authors:  E Martino; L Bartalena; F Bogazzi; L E Braverman
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  Quantification of iodine supply: representative data on intake and urinary excretion of iodine from the German population in 1996.

Authors:  Friedrich Manz; Thomas Böhmer; Roland Gärtner; Rolf Grossklaus; Martin Klett; Roland Schneider
Journal:  Ann Nutr Metab       Date:  2002       Impact factor: 3.374

Review 3.  Antithyroid drugs.

Authors:  David S Cooper
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

Review 4.  The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health.

Authors:  Michael B Zimmermann; Josef Köhrle
Journal:  Thyroid       Date:  2002-10       Impact factor: 6.568

5.  Selenium-dependent cellular glutathione peroxidase protects mice against a pro-oxidant-induced oxidation of NADPH, NADH, lipids, and protein.

Authors:  W Cheng; Y X Fu; J M Porres; D A Ross; X G Lei
Journal:  FASEB J       Date:  1999-08       Impact factor: 5.191

6.  [Guideline for radioiodine therapy for benign thyroid diseases (version 3)].

Authors:  M Dietlein; J Dressler; F Grünwald; B Leisner; E Moser; Chr Reiners; H Schicha; P Schneider; O Schober
Journal:  Nuklearmedizin       Date:  2004-12       Impact factor: 1.379

7.  Scintigraphy for risk stratification of iodine-induced thyrotoxicosis in patients receiving contrast agent for coronary angiography: a prospective study of patients with low thyrotropin.

Authors:  Eva Fricke; Harald Fricke; Elke Esdorn; Annett Kammeier; Oliver Lindner; Knut Kleesiek; Dieter Horstkotte; Wolfgang Burchert
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

Review 8.  [Problems and new developments in the management of Graves' disease: medical therapy].

Authors:  B Quadbeck; O E Janssen; K Mann
Journal:  Z Arztl Fortbild Qualitatssich       Date:  2004-05

9.  The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area.

Authors:  Henry Völzke; Jan Lüdemann; Daniel M Robinson; Knut W Spieker; Christian Schwahn; Axel Kramer; Ulrich John; Wieland Meng
Journal:  Thyroid       Date:  2003-08       Impact factor: 6.568

10.  Supplementation with antioxidants in the treatment of Graves' disease; the effect on glutathione peroxidase activity and concentration of selenium.

Authors:  Vesna Bacic Vrca; Franjo Skreb; Ivana Cepelak; Zeljko Romic; Ljiljana Mayer
Journal:  Clin Chim Acta       Date:  2004-03       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.